News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

GlaxoSmithKline (GSK) Sells Europe OTC Brands, Except Alli, to Omega Pharma NV (0OMEP.BR)


3/15/2012 7:46:58 AM

GlaxoSmithKline has agreed to sell several over-the-counter healthcare brands in Europe to Belgium's Omega Pharma for 470 million euros ($612 million), while delaying the divestment of its weight-loss pill Alli. The decision to put the sale of Alli on hold follows an interruption in supplies from Roche, which makes the active ingredient for the product, a company spokeswoman said. Net cash proceeds from the sale to Omega are expected to be approximately 310 million pounds ($486 million), which will be returned to shareholders during 2012, GSK said on Thursday.

Read at Reuters
Read at Market Watch
Read at Fox News
Read at Nasdaq
Read at Bloomberg


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES